New Study Adds Vytorin Woes For Merck, Schering
Merck & Co. and Schering-Plough Corp. are facing an increasingly uphill battle to ward off concerns over their jointly marketed cholesterol treatment Vytorin, with a new study reportedly showing that the...To view the full article, register now.
Already a subscriber? Click here to view full article